Replimune's Runway Tightens as the FDA Decision Clock Keeps Running
Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.
Part 2.1: Price Behavior Around Earnings
REPL typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.
| Earnings Date | Day 0 Move | Day 0 Range | Day +1 Move | Day +1 Range |
|---|---|---|---|---|
| 2026-06-29 | -$0.43 (-3.70%) | $0.74 (6.36%) | -$0.13 (-1.16%) | $1.53 (13.66%) |
| 2026-02-03 | +$0.41 (+5.81%) | $0.52 (7.46%) | -$0.38 (-5.15%) | $0.70 (9.49%) |
| 2025-11-06 | -$0.08 (-0.93%) | $0.36 (4.20%) | -$0.19 (-2.24%) | $0.65 (7.65%) |
| 2025-08-07 | -$0.02 (-0.36%) | $0.51 (9.27%) | -$0.19 (-3.47%) | $0.48 (8.67%) |
| 2025-05-22 | +$0.30 (+3.55%) | $1.64 (19.35%) | -$0.41 (-4.68%) | $0.94 (10.67%) |
| 2025-02-12 | +$0.94 (+7.32%) | $1.49 (11.60%) | +$0.50 (+3.63%) | $1.04 (7.54%) |
| 2024-11-12 | -$0.31 (-2.48%) | $1.15 (9.17%) | -$0.50 (-4.10%) | $1.11 (9.11%) |
| 2024-08-08 | +$0.25 (+2.72%) | $0.77 (8.37%) | +$0.13 (+1.38%) | $0.64 (6.77%) |
| Avg Abs Move | 3.36% | 9.47% | 3.22% | 9.20% |
Historical price action shows moderate volatility around earnings events, with an average absolute Day 0 move of 3.36% and Day +1 move of 3.22%. The intraday ranges are notably wider, averaging 9.47% on Day 0 and 9.20% on Day +1, indicating significant intraday swings even when closing moves are more contained. The most recent earnings (June 2026) saw a -3.70% Day 0 decline with a 6.36% intraday range, followed by relatively modest Day +1 movement. The largest reactions occurred in February 2025 (+7.32% Day 0) and May 2025 (+19.35% intraday range), suggesting the stock can experience sharp moves when results or commentary significantly surprise the market. Overall, investors should anticipate mid-single-digit percentage moves with potential for larger swings if clinical updates or cash guidance deviate materially from expectations.
Part 2.2: Options Market Expected Move
| Metric | Value |
|---|---|
| Expiration Date | 08/14/26 (DTE 2) |
| Expected Move | $0.89 (5.86%) |
| Expected Range | $14.35 to $16.13 |
| Implied Volatility | 125.72% |
The options market is pricing an expected move of 5.86% through the August 14 weekly expiration, which is notably higher than the historical average Day 0 move of 3.36% but well below the average intraday range of 9.47%. This suggests options traders are anticipating above-average volatility for this release compared to typical closing moves, though still within the range of historical intraday swings.
Part 3: What Analysts Are Saying
Analysts maintain a bullish stance on REPL with an average recommendation of 4.33 out of 5.00, reflecting strong buy sentiment. The current consensus includes 7 Strong Buy ratings, 0 Moderate Buys, 1 Hold, 0 Moderate Sells, and 1 Strong Sell among 9 analysts covering the stock. This represents significantly improved sentiment from one month ago when the average recommendation stood at 3.44 with only 3 Strong Buys and 5 Holds, indicating several analysts have upgraded their outlook recently.
The average price target of $19.00 implies 25% upside from the current price of $15.24, with estimates ranging from a low of $14.00 (8% downside) to a high of $24.00 (57% upside). The wide target range reflects differing views on the company's clinical pipeline value and probability of success, typical for pre-revenue biotechnology companies where valuation depends heavily on binary clinical and regulatory outcomes. The recent wave of upgrades suggests growing analyst confidence in REPL's development programs and potential commercial opportunity, though the presence of one Strong Sell rating indicates not all analysts share the optimistic view.
Part 4: Technical Picture
REPL enters earnings with strong technical momentum, as the Barchart Technical Opinion currently stands at 88% Buy, up from 80% Buy one week ago and 72% Buy one month ago. This steady improvement in the signal reflects sustained buying pressure and positive price action heading into the release.
Timeframe Analysis:
- Short-term (100% Buy): Maximum bullish signal indicates powerful near-term momentum with no technical resistance from recent price action
- Medium-term (100% Buy): Equally strong reading confirms the uptrend is well-established beyond just short-term trading, suggesting institutional accumulation
- Long-term (50% Buy): Moderate bullish signal shows the stock has made progress but still faces some longer-term technical overhead or consolidation patterns
Trend Characteristics: The combination of Maximum strength and Strongest direction indicates REPL is in an exceptionally robust uptrend with powerful momentum across multiple timeframes heading into earnings.
The stock is trading above all major moving averages, including the 5-day ($13.50), 10-day ($11.98), 20-day ($10.78), 50-day ($10.45), 100-day ($7.59), and 200-day ($8.10). This complete alignment with the current price above every key average is a textbook bullish setup, though it also means the stock has limited nearby support if earnings disappoint.
| Period | Value | Period | Value |
|---|---|---|---|
| 5-Day MA | $13.50 | 50-Day MA | $10.45 |
| 10-Day MA | $11.98 | 100-Day MA | $7.59 |
| 20-Day MA | $10.78 | 200-Day MA | $8.10 |
The current price of $15.24 represents a significant extension above even the shortest-term moving averages, with the stock trading 13% above its 5-day MA and 88% above its 200-day MA. This stretched positioning creates a double-edged setup: momentum is clearly strong, but the lack of nearby technical support means any disappointment could trigger a sharp pullback toward the $13.50-$11.98 zone where the 5-day and 10-day averages reside. The Maximum strength rating and position above all moving averages suggest the path of least resistance remains higher if earnings meet or exceed expectations, but the extended nature of the rally leaves little room for error.